📰 Session Number News
Session Number News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Session Number. Real-time updates on events, politics, business and more.
May 3, 2023
Further data from study 014/015 of evenamide in treatment-resistant schizophrenia confirms potentially relevant role of glutamatergic release modification when added to TRS patients not responding... | May 3, 2023
December 9, 2022
Retail industry news, voices and jobs. Optimized for your mobile phone.
December 1, 2022
21 scientific presentations, including 7 late breakers, showcase the breadth of UCBs portfolio, reinforcing commitment to improving the lives of people living...
July 14, 2022
The abstract suggests that BBT-176 has shown its capability of inducing clinical tumor responses in EGFR triple mutation-containing patients Further exploration of the drug
March 17, 2022
Kite, a Gilead Company, presents long-term CAR T cell therapy data in lymphomas at the 48th EBMT Annual Meeting Primary analysis of pivotal data on earlier use of CAR T cell therapy as second-line treatment in relapsed/refractory diffuse large B cell lymphomaLong-term overall survival and safety management data...
August 11, 2021
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
March 11, 2021
Message : Required fields -- AFM24 preclinical in vivo data will be presented as a poster -- Data on AFM13 in combination with adoptive NK cells will be presented during a Major Symposium Heidelberg, Germany, March 10, 2021 -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that preclinical anti-tumor efficacy in vivo data from its innate cell engager (ICE(R) ) AFM...